Specialty pharmaceutical company Collegium Pharmaceutical reached a $2.75 million agreement with the U.S. government to settle 27 pending lawsuits related to the opioid crisis and the company’s sale of Xtampza.
U.S. states are racing to meet a deadline to commit to a $26 billion opioid settlement with three drug distributors and the drugmaker Johnson & Johnson, as some grapple with local resistance and concerns the amount is not large enough to address the damage done by an epidemic of addiction.
A federal appeals court overturned a judge’s approval of a novel plan by lawyers representing cities and counties suing drug companies over the U.S. opioid crisis that would bring every community nationally into their settlement talks.
A federal judge partially overturned the convictions of Insys Therapeutics Inc.’s founder and three former executives accused of bribing doctors to prescribe an addictive opioid, but declined to disturb the remainder of the jury’s verdict.
Purdue Pharma LP will ask a U.S. Bankruptcy Judge to pause litigation against the company and ownership over the objections of U.S. states that allege the OxyContin maker is trying to protect the controlling Sackler family.